DeBeurs.nl

flosz 18 augustus 2009 16:25

2

quote:
flosz schreef:
Project Number: 5U19AI078526-02
Sub-Project ID: 0003
Principal Investigator (PI): GOUDSMIT, JAAP
Organization: CRUCELL HOLLAND, BV
Title: MANUFACTURING OF NOVEL ADENOVIRUS PRIME-BOOST HIV-1 VACCINE

Budget Start Date:1-AUG-2009
Budget End Date:31-JUL-2010

Year 2009
Funding IC NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES
FY Total Cost by IC$11,476,040

Project Number: 1U19AI078526-01
Sub-Project ID: 0003
Principal Investigator (PI): GOUDSMIT, JAAP
Title: MANUFACTURING OF NOVEL ADENOVIRUS PRIME-BOOST HIV-1 VACCINE
Organization: CRUCELL HOLLAND, BV

Study Section: ZAI1
Project Start Date: 15-AUG-2008
Project End Date: 31-JUL-2013

Fiscal Year: 2008

Budget End Date: 31-JUL-2009

Year 2008
Funding IC NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES

FY Total Cost by IC $2,669,207

projectreporter.nih.gov/project_info_...

[verwijderd] 27 augustus 2009 12:39

0

August 24, 2009

BULLETIN

HVTN 505 HIV Vaccine Study Begins Enrolling Volunteers

The National Institute of Allergy and Infectious Diseases (NIAID), part of the NIH, has opened enrollment in HVTN 505, an exploratory HIV vaccine clinical study examining whether a two-part vaccine regimen can decrease viral load (the amount of HIV in the blood) in study participants who later become infected with HIV. Viral load is an important health indicator in people who are infected with HIV because typically those with less virus remain healthier longer. Further, HIV-infected individuals with reduced levels of virus may be less likely to transmit the virus to other people.

Led by Scott M. Hammer, M.D., chief of the Division of Infectious Diseases at Columbia University in New York, HVTN 505 is being conducted by the NIAID-supported HIV Vaccine Trials Network (HVTN). The Phase II study employs a prime-boost strategy of two investigational vaccines developed by scientists at NIAID’s Vaccine Research Center (VRC): a series of three immunizations with recombinant DNA-based vaccine (the primer vaccine) over the course of eight weeks followed by a single immunization with a recombinant vaccine (the boosting vaccine) based on a weakened adenovirus type 5 (Ad5) that carries the vaccine contents and helps stimulate the immune system. Ad5 is a common virus that normally causes colds, but the Ad5 virus used in the VRC vaccine regimen has been disabled so that it cannot cause a cold or other respiratory illness. The Ad5 vaccine in this study encodes for HIV proteins found both inside the virus and on its outer envelope.

Neither of the two vaccines contains HIV and neither vaccine can infect study participants with the virus. Both vaccines have been found safe when tested in animals and when used in hundreds of people in earlier clinical trials.

HVTN 505 is planned to take place in 12 U.S. cities and is designed to enroll 1,350 HIV-negative men ages 18 to 45 years who have sex with men. Participants must be circumcised and at the time they are enrolling, without Ad5 antibodies resulting from previous exposure to the Ad5 virus. These enrollment requirements are in place as an added safety precaution because in the HIV vaccine study known as Step (see Statement: Immunizations Are Discontinued in Two HIV Vaccine Trials), which involved a slightly different Ad5 vaccine, more cases of infection were found among those gay and bisexual male participants who were not circumcised and who had Ad5 antibodies at the time of enrollment compared to participants with the same characteristics who were given a placebo vaccine.

The HVTN 505 study is intended to answer important scientific questions that could lead to the discovery and development of new and improved candidate HIV vaccines in the future. An exploratory study such as this is not part of a typical product development path of studies that would lead to vaccine licensure. Rather, this type of study serves as the basis for subsequent research that will build upon its findings.

For more information about the HVTN 505 study, see Questions and Answers: The HVTN 505 HIV Vaccine Regimen Study and www.hopetakesaction.org.

www3.niaid.nih.gov/news/newsreleases/...

ved 4 september 2009 11:27

2

Science briefing: Antibodies boost Aids vaccine hunt
By Clive Cookson

Published: September 4 2009 01:56 | Last updated: September 4 2009 01:56

Antibodies boost Aids vaccine hunt

Researchers in the US have discovered two powerful new antibodies to HIV, which may rejuvenate the flagging search for an Aids vaccine. The discovery, reported online in the journal Science, reveals the virus has a previously unknown Achilles heel

Scientists at the International Aids Vaccine Initiative (IAVI) worked with the Scripps Research Institute and two biotechnology companies, Theraclone Sciences and Monogram Biosciences, to find the “broadly neutralising” antibodies, which are produced by a small minority of HIV-infected
people.

Both antibodies neutralise a large proportion of the many HIV strains in circulation worldwide. They seem to target a region on the “spike” which the virus uses to infect new cells.

The discovery marks the first success of a search to find broadly neutralising antibodies for use in developing new Aids vaccines, launched by IAVI in 2006. Many experts believe that an effective vaccine – sought unsuccessfully for 25 years – will need to “teach” the human immune system to produce such antibodies before exposure to HIV.

The antibodies were found by screening blood donated by 1,800 HIV-infected volunteers.

www.ft.com/cms/s/0/8578f4bc-98eb-11de...

ved 4 september 2009 12:17

0

quote:
ved schreef:
www.ft.com/cms/s/0/8578f4bc-98eb-11de...

zie ook:

www.iavi.org/research-development/IAV...

www.iavi.org/research-development/IAV...

pardon 6 september 2009 00:03

0

Login My Profile Logout Top News
Reuters top ten news stories delivered to your inbox each day.

Subscribe You are here: Home > News > Science > Article Home
Business & Finance
News
U.S.
Politics
International
Technology
Entertainment
Sports
Lifestyle
Oddly Enough
Health
Science
Special Coverage
Video
Pictures
Your View
The Great Debate
Blogs
Weather
Reader Feedback
Do More With Reuters
RSS
Widgets
Mobile
Podcasts
Newsletters
Your View
Make Reuters My Homepage
Partner Services
CareerBuilder
Affiliate Network
Professional Products
Support (Customer Zone)
Reuters Media
Financial Products
About Thomson ReutersStudy finds potential way to make an AIDS vaccine
Thu Sep 3, 2009 10:08pm EDT
Email | Print | Share| Reprints | Single Page[-] Text [+]
1 of 1Full SizeFeatured Broker sponsored link
By Maggie Fox, Health and Science Editor
WASHINGTON (Reuters) - The discovery of immune system particles that attack the AIDS virus may finally open a way to make a vaccine that could protect people against the deadly and incurable infection, U.S. researchers said on Thursday.

They used new technology to troll through the blood of 1,800 people infected with the AIDS virus and identified two immune system compounds called antibodies that could neutralize the virus.

And they found a new part of the virus that the antibodies attack, offering a new way to design a vaccine, they reported in the journal Science.

"So now we may have a better chance of designing a vaccine that will elicit such broadly neutralizing antibodies, which we think are key to successful vaccine development," said Dennis Burton of The Scripps Research Institute in La Jolla, California, who led the study.

"The findings themselves are an exciting advance toward the goal of an effective AIDS vaccine because now we've got a new, potentially better target on HIV to focus our efforts for vaccine design," added Wayne Koff of the International AIDS Vaccine Initiative, or IAVI, which sponsored the study.

Since the AIDS pandemic started in the early 1980s, more than 25 million people globally have died from the virus. The World Health Organization estimates that 33 million are currently infected.

There is no cure, although a cocktail of drugs can help keep the virus under control. Efforts to make a vaccine have failed almost completely.

MUTABLE VIRUS

Part of this is because the virus mutates so much that any one person is infected with millions of different versions, each one appearing different to the immune system.

In addition, the virus infects the very immune cells that are supposed to help protect the body. And if even one virus gets past the immune defense, it appears to set up a lifelong infection. No drug has been able to eradicate it.

IAVI director Dr. Seth Berkley said the findings will not lead directly to a vaccine, but show that there are new and better ways to design one.

He said 10 percent of the patients whose blood was screened had a strong antibody response to the virus. "We have people with even more potent serum out there. We will probably see more," he said in a telephone interview.

It may also be possible to use such antibodies as therapy themselves -- such as the gamma globulin used for hepatitis virus. But the eventual goal, Berkley said, is a vaccine that produces antibodies that could stop the virus from ever infecting a person in the first place.

"We haven't been able to do that because we haven't been able to find the right kind of response," Berkley said.

Most vaccines elicit an antibody response, priming the body to make antibodies that will recognize and attack an invader such as a bacteria or virus. Continued...

View article on single pagePrevious Page 1 | 2 Next Page

Share:Del.icio.usDiggMixxYahoo!FacebookLinkedIn Next Article: NASA tracks space junk headed toward space station

Also on Reuters
SEC checklist: Fix the mess, find the next MadoffGoogle's investors look for the next big thingChinatrust offers $2.4 billion for AIG Taiwan unitMore Science News
NASA tracks space junk headed toward space station How broccoli can protect your arteries Osiris stem cell platform success hinges on 2 trials Computer algorithm to decipher ancient texts | Video
New-found Asian antelope said close to extinction More Science News...Ads by GoogleWhat's This?
HIV PCR Array
Advanced qPCR Technology for HIV Infection & Host Response
www.SABiosciences.com

What is Scientology?
You Are Not Your Name, Your Job Or The Clothes You Wear. Scientology.
Scientology.org

Beurshandel - Gratis demo
Geen commissie CFD aandelenhandel Hoge leverage. Stort minimaal €100
10Pips.nl/Handel-Aandelen

Better Immunity 200mgx60
Beta Glucan-immunity enhancer-$9.95 Free Library and Weekly Newsletter
www.youngagain.com

Editor's Choice

Slideshow A selection of our best photos from the past 24 hours. Slideshow
Search ResultsResults for ""More results for ""...
Most Popular on ReutersArticlesVideo1.Police in Georgia arrest man in trailer killings
2.Website says to carry bin Laden "present" to Muslims
3.California's Real Death Panels: Insurers Deny 21% of Claims
4.Amazon offers to replace deleted copies of 1984
5.UPDATE 1-Boeing tanker backers seize on WTO ruling
6.Obama unveils measures to spur U.S. retirement saving
7.McChrystal tries to calm Afghans after air strike
8.SEC chiefs in dark as Madoff evaded junior staff
9.Got a dream but no cash? The Internet can help
10.Five banks closed by U.S. regulators
Most Popular Articles RSS Feed Video US eases travel curbs for Cuba Aftermath of Afghan tanker airstrike Many dead in NATO Afghan blast U.S. jobless rate at 26-yr peak Macedonia ferry disaster DNA to prove attack on Mayan city Brave new chapter for author Atwood UK Brown urges continued support Michael Jackson laid to rest Gabon curfew after poll protests Most Popular Videos RSS Feed. Reuters.com: Help and Contact Us | Advertise With Us | Mobile | Newsletters | RSS | Labs | Journalism Handbook | Archive | Site Index | Video Index

Thomson Reuters Corporate: Copyright | Disclaimer | Privacy | Professional Products | Professional Products Support | About Thomson Reuters | Careers

International Editions: Africa | Arabic | Argentina | Brazil | Canada | China | France | Germany | India | Italy | Japan | Latin America | Mexico | Russia | Spain | United Kingdom | United States

Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.

NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

aossa 6 september 2009 12:17

0

Mijk, daar hebben we wat aan <NOT>
Gelieve jouw artikels te zuiveren van SPAM en andere rommel voordat je ze post of nadien bmb de tab 'Bewerk', die staat er voor iets. Het is niet de eerste keer dat we die rotzooi meekrijgen van jou. Merci, Dankewel, Grazias, Vielen Dank, Per Favor etc...

quote:
pardon schreef:
Login My Profile Logout Top News
Reuters top ten news stories delivered to your inbox each day.

Subscribe You are here: Home > News > Science > Article Home
Business & Finance
News
U.S.
Politics
International
Technology
Entertainment
Sports
Lifestyle
Oddly Enough
Health
Science
Special Coverage
Video
Pictures
Your View
The Great Debate
Blogs
Weather
Reader Feedback
Do More With Reuters
RSS
Widgets
Mobile
Podcasts
Newsletters
Your View
Make Reuters My Homepage
Partner Services
CareerBuilder
Affiliate Network
Professional Products
Support (Customer Zone)
Reuters Media
Financial Products
About Thomson ReutersStudy finds potential way to make an AIDS vaccine
Thu Sep 3, 2009 10:08pm EDT
Email | Print | Share| Reprints | Single Page[-] Text [+]
1 of 1Full SizeFeatured Broker sponsored link
By Maggie Fox, Health and Science Editor

...
View article on single pagePrevious Page 1 | 2 Next Page

Share:Del.icio.usDiggMixxYahoo!FacebookLinkedIn Next Article: NASA tracks space junk headed toward space station

Also on Reuters
SEC checklist: Fix the mess, find the next MadoffGoogle's investors look for the next big thingChinatrust offers $2.4 billion for AIG Taiwan unitMore Science News
NASA tracks space junk headed toward space station How broccoli can protect your arteries Osiris stem cell platform success hinges on 2 trials Computer algorithm to decipher ancient texts | Video
New-found Asian antelope said close to extinction More Science News...Ads by GoogleWhat's This?
HIV PCR Array
Advanced qPCR Technology for HIV Infection & Host Response
www.SABiosciences.com

What is Scientology?
You Are Not Your Name, Your Job Or The Clothes You Wear. Scientology.
Scientology.org

Beurshandel - Gratis demo
Geen commissie CFD aandelenhandel Hoge leverage. Stort minimaal €100
10Pips.nl/Handel-Aandelen

Better Immunity 200mgx60
Beta Glucan-immunity enhancer-$9.95 Free Library and Weekly Newsletter
www.youngagain.com

Editor's Choice

Slideshow A selection of our best photos from the past 24 hours. Slideshow
Search ResultsResults for ""More results for ""...
Most Popular on ReutersArticlesVideo1.Police in Georgia arrest man in trailer killings
2.Website says to carry bin Laden "present" to Muslims
3.California's Real Death Panels: Insurers Deny 21% of Claims
4.Amazon offers to replace deleted copies of 1984
5.UPDATE 1-Boeing tanker backers seize on WTO ruling
6.Obama unveils measures to spur U.S. retirement saving
7.McChrystal tries to calm Afghans after air strike
8.SEC chiefs in dark as Madoff evaded junior staff
9.Got a dream but no cash? The Internet can help
10.Five banks closed by U.S. regulators
Most Popular Articles RSS Feed Video US eases travel curbs for Cuba Aftermath of Afghan tanker airstrike Many dead in NATO Afghan blast U.S. jobless rate at 26-yr peak Macedonia ferry disaster DNA to prove attack on Mayan city Brave new chapter for author Atwood UK Brown urges continued support Michael Jackson laid to rest Gabon curfew after poll protests Most Popular Videos RSS Feed. Reuters.com: Help and Contact Us | Advertise With Us | Mobile | Newsletters | RSS | Labs | Journalism Handbook | Archive | Site Index | Video Index

Thomson Reuters Corporate: Copyright | Disclaimer | Privacy | Professional Products | Professional Products Support | About Thomson Reuters | Careers

International Editions: Africa | Arabic | Argentina | Brazil | Canada | China | France | Germany | India | Italy | Japan | Latin America | Mexico | Russia | Spain | United Kingdom | United States

Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.

NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

[verwijderd] 6 september 2009 13:44

0

@ Aossa..

Gelieve jouw artikels te zuiveren van SPAM en andere rommel voordat je ze post of nadien bmb de tab 'Bewerk', die staat er voor iets. Het is niet de eerste keer dat we die rotzooi meekrijgen van jou. Merci, Dankewel, Grazias, Vielen Dank, Per Favor etc...

:-)

Dirk

aossa 6 september 2009 13:47

0

@Dirk

Doe ik geregeld, maar ja, soms slipt er eens wat tussendoor :-D

Maar quoten doe ik daargaans goed!
Moet je die ellenlange rotzooi van pardon eens mee vergelijken. Lees ik gewoon niet meer, zelfs niet het mogelijk interessant artikel dat ertussen geprangd zit.

BTW. @pardon: ipv te quoten is een link ook goed, leest in ieder geval beter en we hebben direct de bron beet.

:-))) No revange!

[verwijderd] 6 september 2009 13:53

0

Het motto van Pardon is waarschijnlijk:

"Enfin, om een kort verhaal lange te maken"

:> }

Dirk

MeawandMoo1 9 september 2009 21:44

0

quote:
flosz schreef:
Project Number: 5U19AI078526-02
Sub-Project ID: 0003
Principal Investigator (PI): GOUDSMIT, JAAP
Organization: CRUCELL HOLLAND, BV
Title: MANUFACTURING OF NOVEL ADENOVIRUS PRIME-BOOST HIV-1 VACCINE

Budget Start Date:1-AUG-2009
Budget End Date:31-JUL-2010

Year 2009
Funding IC NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES
FY Total Cost by IC$11,476,040

projectreporter.nih.gov/project_info_...

Even hulp gevraagd op dezelfde link.
5U19AI078526-02
0003
MANUFACTURING OF NOVEL ADENOVIRUS PRIME-BOOST HIV-1 VACCINE
GOUDSMIT, JAAP CRUCELL HOLLAND, BV
2009 NIAID

$10,842,163

Bedragen zijn aangepast, wel nog steeds cursief, maar nu wel opgenomen op de "voorpagina".

Is mijn constatering juist? Dan zou -mogelijk- het aangevraagde budget akkoord zijn.

[verwijderd] 11 september 2009 12:40

0

Most Pharmaceutical Companies Receive Poor Grades on HIV/AIDS Drug Development Innovation, According to AIDS Treatment Activist Coalition Report Card
Last update: 9/10/2009 2:05:00 PM

--Many Companies Get Low Marks in Five Benchmark Treatment Categories; New Drugs Need to Reflect Long-Term Care Strategy NEW YORK, Sept 10, 2009 /PRNewswire via COMTEX/

-- With the estimated 1.2 million people with HIV/AIDS in the United States expected to live close to a normal life span, the majority of pharmaceutical companies are not developing innovative, new long-term treatment options that offer improved efficacy, safety and tolerability when taken for decades, according to a report card on the pharmaceutical industry released today by the AIDS Treatment Activists Coalition's (ATAC) Drug Development Committee.

ATAC, , is a national non-profit AIDS advocacy group working to end the AIDS epidemic by advancing research of HIV/AIDS. The ATAC Pharmaceutical Company HIV/AIDS Report Card ranks the nine largest pharmaceutical companies (Abbott Laboratories, Boehringer Ingelheim, Bristol-Myers Squibb, Gilead Sciences, GlaxoSmithKline, Hoffman La Roche, Merck & Co., Pfizer and Tibotec) with HIV/AIDS drugs on the market in five categories: drug development portfolio and plans, access to drugs, pricing, community relations and marketing practices.

The average final grade was a C-: Abbott Laboratories received the lowest grade, an F, and Merck & Co. and Tibotec each received the highest grade, a B. The companies were issued a letter grade from A-F for each of the five categories as well as a final grade average. To view the companies' grades, view .

ATAC gave most companies low marks in five benchmark treatment categories:
-- Drug Development and Plans: The pipeline is shrinking, investment is falling, and in some cases, cooperation with the community has been diminishing.
This adds up to fewer truly innovative new drugs and the possibility that clinical trials could be less safe or less likely to get relevant information.
-- Access to Treatment: With fewer drugs in the pipeline that will be useful for people who have already used existing treatments, early access to potentially life-saving treatment is a growing concern.
-- Pricing: HIV/AIDS drugs are among the most highly priced on the market, and price increases taken by most companies have been at least double the rate of inflation. This means fewer low income people can be accepted into government programs, and most people with HIV are paying higher insurance co-payments.
-- Community Relations: Many companies are less willing to seek independent input from the U.S. HIV/AIDS community regarding research and trials, particularly in the early stages of the drug development process. This is putting trial participants at a greater risk for illness and treatment failure.
-- Marketing Practices: Negative or misleading advertising has serious consequences for people with HIV/AIDS; potentially causing alarm if they are taking competing drugs, or stoppage of a current regimen before consulting with their provider. Some companies have sometimes overstated efficacy, safety, or are marketing drugs for non-approved uses.

Dirk

custom.marketwatch.com/custom/tdameri...

[verwijderd] 11 september 2009 12:51

0

EN DUS???????

[verwijderd] 15 september 2009 13:46

0

Shionogi & Co: Drug Jointly Developed With GlaxoSmithKline
Last update: 9/15/2009 12:29:56 AM

TOKYO (Dow Jones)--Shionogi & Co. Ltd. (4507.TO) said Tuesday early clinical studies on an experimental drug jointly developed with GlaxoSmithKline PLC (GSK) for treating HIV infection produced favorable efficacy and safety results.

The phase-1 and -2 studies on S/GSK1265744 demonstrated the drug's effectiveness in reducing levels of infection in patients, and showed a good short-term safety profile, Shionogi said in a statement.

Shionogi and GSK are also jointly developing an HIV drug with the same treatment mechanism, S/GSK1349572, which is in phase-2 studies. -By Kazuhiro Shimamura, Dow Jones Newswires; 813-6895-7566; kazuhiro.shimamura@dowjones.com (END)

Dow Jones NewswiresSeptember 15, 2009 00:28 ET (04:28 GMT)

DRW

flosz 23 september 2009 20:02

0

Via Yahoo-GNVC mb.

HIV Vaccine Study May Lift Hopes After Merck, Sanofi Setbacks
Sept. 23 (Bloomberg) -- The search for a vaccine to prevent HIV has eluded scientists for a quarter of a century. They will find out if they are a step closer when the results of the world’s largest HIV vaccine trial are presented tomorrow.
The U.S.-funded study of 16,000 volunteers involves a vaccine that combines two older shots developed by Sanofi- Aventis SA and VaxGen Inc.
While scientists aren’t holding out for a major breakthrough, they are hopeful the data will give them some indication that they are heading in the right direction, said Marie-Paule Kieny, director of the World Health Organization’s Initiative for Vaccine Research in Geneva.
The results presented in Bangkok may be the first turning point since 2007, when an attempt by Whitehouse Station, New Jersey-based Merck & Co. was terminated after the shot appeared to boost people’s chances of becoming infected. It was one of several fizzled attempts to slow the spread of AIDS, which infects about 6,800 new people every day.
“I don’t think there is a lot of expectation that the efficacy of this vaccine will be very high,” Kieny said in a telephone interview from Oxford, England. “Any hint towards identifying something which is protective in humans would be good news.”
The Thai study looked at whether different infection- fighting strategies devised by Paris-based Sanofi and VaxGen could be combined in a two-pronged approach.
Trojan Horse
The first vaccine, called ALVAC, uses a canarypox virus that’s been disabled so as not to cause sickness in humans as a Trojan horse to smuggle three genetic fragments of HIV into the body. It’s designed to coax the immune system to issue so-called T-cells to hunt and kill infected cells.
The second shot, called AIDSVAX, contains an HIV protein called gp120 that the virus uses to enter human cells. It’s designed to encourage the body to produce neutralizing antibodies to destroy HIV viruses before they infect healthy cells.
Both vaccines failed in previous trials where they were tested separately. Sanofi, which made ALVAC, stopped development of the shot after a study showed it didn’t boost the body’s immune system. VaxGen, a venture spun off in 1995 from South San Francisco, California-based biotech company Genentech Inc., ceased development of AIDSVAX in 2003 after a trial showed it didn’t prevent people from getting HIV.
The Global Solutions for Infectious Diseases, a South San Franciso-based non-profit organization, acquired the rights to VaxGen’s shot.
‘Glimmer of Success’
In 2004, a group of U.S. AIDS researchers said in a letter to the journal Science that the trial of the combined vaccines would probably disappoint and shouldn’t be allowed to proceed because of the failure of the two previous studies.
“Many people in the vaccine research field will not be surprised if the ALVAC-AIDSVAX vaccine regimen proves to be ineffective,” the New York-based AIDS Vaccine Advocacy Coalition said in a preview of the trial results e-mailed to Bloomberg. “However, history tells us that the development of any vaccine involves decades of work and a range of disappointments before the first glimmer of success.”
The researchers enrolled volunteers in Thailand’s Chon Buri and Rayong provinces, which have the nation’s highest rates of HIV, according to the study Web site. Subjects were given four doses of the ALVAC vaccine and two of the AIDSVAX shot over six months, then monitored for three years. They were also given condoms and advice on safe sex.
An interim analysis in July 2007 showed there were no safety concerns with the vaccines, the researchers said at the time.
The trial was funded by the National Institute of Allergy and Infectious Diseases, the National Institutes of Health and the U.S. Army Medial Research and Materiel Command.
bloomberg.com/apps/news?pid=20601124&...

flosz 24 september 2009 09:29

0

Sanofi Pasteur Commends Results
of First HIV Vaccine Study to Show
Some Effectiveness in Preventing HIV

…..safe and modestly effective in preventing HIV infection.
en.sanofi-aventis.com/binaries/200909...

[verwijderd] 24 september 2009 13:09

0

2nd UPDATE: AIDS Vaccine Cuts Infection Risk - Researchers
Last update: 9/24/2009 4:01:30 AM(Updates with further quotes about trials from officials, names of companies involved, details of trial, reactions; adds background)

BANGKOK (AFP)--An experimental AIDS vaccine has cut the risk of infection in a "breakthrough" in the quarter-century battle against the deadly epidemic, researchers said Thursday.

The vaccine reduced the risk of being infected by almost a third, they said, following a trial of more than 16,000 volunteers.

It was carried out by the U.S. Army and Thailand's Ministry of Public Health. "It is the first demonstration that a vaccine against HIV can protect against infection," Col.

Jerome Kim of the U.S. military HIV research program told a news conference in Bangkok by video link.

"This is a very important scientific advance and gives us hope that a globally effective vaccine may be possible in the future," he said.

The vaccine was a combination of two older vaccines that hadn't reduced infection on their own, and the researchers said they were now studying why the two vaccines apparently worked together.

The study combined the canarypox vaccine ALVAC, manufactured by Sanofi-Aventis SA (SAN.FR) of France, and AIDSVAX, originally made by VaxGen Inc. (VXGN) and now licensed to Global Solutions for Infectious Diseases.

"The outcome represents a breakthrough in HIV vaccine development because for the first time ever there is evidence that HIV vaccine has preventative efficacy," said a statement released by the researchers. "The vaccine has a 31.2% efficacy in reducing the risk of HIV infection." It was tested on volunteers - all HIV negative men and women ages 18 to 30 - at average risk of infection in two Thai provinces near Bangkok starting in October 2003. Half received the vaccine and the rest were given a placebo. Out of the placebo recipients 74 of 8,198 became infected compared with 51 of 8,197 who got the vaccine.

Thai Public Health Minister Witthaya Kaewparadai said the "outcome of this study is a scientific breakthrough." AIDS first came to public notice in 1981 and has since killed at least 25 million people worldwide, and 33 million others are living with AIDS or the HIV virus. Swift progress in identifying the virus that caused it unleashed early optimism that a vaccine would quickly emerge.

HIV destroys immune cells and exposes the body to opportunistic disease. However, out of the 50 candidates that have been evaluated among humans, only two vaccines have made it through all three phases of trials, and both were flops. About 30 vaccines remain in the pipeline.

U.S. Ambassador to Thailand Eric John told the news conference in Bangkok that the vaccine trial had "incredible conclusions and brought us one step closer to an HIV vaccine." He said more research was needed to find out why the combination of the two previously ineffective vaccines worked, but added that the results had "important implications" for a future vaccine. Sanofi Pasteur, the vaccines division of Sanofi-Aventis, said the trials were the "first concrete demonstration" that a vaccine "could one day become a reality."

"Although modest, the reduction in risk of infection by HIV is statistically significant," said Michel DeWilde, senior vice president for research and development at Sanofi Pasteur. In New York, the International AIDS Vaccine Initiative, or IAVI, an organization that promotes the search for a vaccine, said the trial results were "very exciting and a significant scientific achievement."

"It's the first demonstration that a candidate AIDS vaccine provides benefit in humans. Until now, we've had evidence of feasibility for an AIDS vaccine in animal models," IAVI president Seth Berkley said in a statement. Earlier this month in a study published in the journal Science, U.S. researchers said they had discovered two powerful new antibodies that could hold the key to achieving a viable AIDS vaccine. (END)

Dow Jones NewswiresSeptember 24, 2009 04:01 ET (08:01 GMT)

eddy59 24 september 2009 19:53

0

SNELNIEUWS
Donderdag 24 september
rss Binnen- en Buitenland 19:43 'Geitmens' geboren in Afrika 19:42 Einde id-fraude nachtmerrie in... 19:07 Inbreker zit naakt op bed meisje 18:52 Weer meerderheid Democraten 18:52 Oorlog aan kernwapens 18:52 Man kweekt Boeddha-peren 18:19 'Zet leger in tegen relschoppers' 18:13 Student sleept IBG voor rechter 18:07 Den Haag zet jongeren in 17:21 Voor 200 euro in de Bondsdag 17:19 Verdachte VS wilde... 17:16 Huisgenoot rijdt cabrio water in 17:03 Jongen rijdt in op straatcoaches 16:59 Damherten zorgen voor overlast 16:57 Verdachten schietpartij wethouder... 16:54 Onderzoek optreden IGZ neuroloog 16:54 Terreuralarm Duits vliegveld 16:54 Dode door aanrijding bij Varsseveld 16:28 Stad dokt 12,5 mln voor bouwput 16:11 Seksarmbandjes hype op scholen 16:08 VN tegen verspreiding kernwapens 15:50 Taxichauffeur schuldig aan dood... 15:47 Achtjarige schiet zusje (2) dood 15:46 Man filmt Bigfoot in tuin 15:41 'Tabaksaccijns verhogen met 10%' 15:26 Sydney weer helder 15:24 'Lening directeur onbegrijpelijk' 15:11 'Gracias Máxima' 15:09 Sexy Steini-meisje hit op internet 15:05 Weer terreurdreiging NYC rss Video's Hillary Swank in lingerieshow! Marathon bekeuringen uitschrijven... Klagen over kinderherrie verboden! Jack Wouterse lieveling... Lek vloeibare hars verwond fietser Porsche Panamera Ali B: 'Ik zou 100 keer gratis... Plasticflessen boot promoot... Dilemma: potje Wii of boeven... Ellen Kloos: 'Dressuurles gehad... Naar Video's
rss Telesport Eventingruiters in middenmoot Ajax speelt zonder Suarez Zoer even onder het mes Grinham naar kwartfinales WK Geslaagde missie Moerenhout Naar Telesport
rss Privé Leontine Borsato: 'We slaan ons er doorheen' Saved By The Bell-acteur klapt uit school Liz wil rustplaats naast Jackson Frans Bauer is liever breed Valerio wil niet over seks praten Naar Privé
rss Vrouw Weinig vrouwelijke professoren in ons land De andere man... Peep toe pump Kunstige kralen Liefde is vuur, maar... De moed van een saaie zus Meisjes willen waarschuwing bij nepmodellen Naar Vrouw
rss DFT Amerikaanse beurzen omlaag GM en Reva maken goedkoop elektrisch autootje Rijksambtenaar mag doorwerken na 65 Wellink: meer wetgeving nodig rond bonus Nieuw financiëel topman voor Nieuwe Steen Naar DFT
rss OverGeld 'Tabaksaccijns verhogen met 10%' Typefout kost man 43.000 euro Twintig euro per cadeautje Zin en onzin over de partnertoeslag Toezichthouder doet onderzoek naar notarissen Naar OverGeld
rss DigiTaal Apple en Eminem voor de rechter Google aast op één overname per maand Programma’s SBS op YouTube Nieuwe worm teistert Twitter Belasting over Britse telefoonaansluitingen Naar DigiTaal
rss Eten en Genieten Nationale Restaurantbon verkocht ’Oesters van goede kwaliteit’ Anders en fris bij Fleurie Gratis voedsel in supermarkt kan Hobbykok van het jaar 2009 Naar Eten en Genieten
rss Games 'Cruciaal jaar voor gamesindustrie' Lente brengt Motion Controller voor... Ook 250GB PS3-bundels naar Nederland Review: WET (Xbox 360/PS3) Geruchten rond overnames game-uitgevers Naar Games
rss Reiskrant Dieren in de uitverkoop Londen in de uitverkoop Er was eens... Smullen in Zwolle Je kunt de boom in! Naar Reiskrant
rss Auto Duitsland verdedigt staatssteun aan Opel Fiat niet op Bologna-autoshow Mercedes overweegt Amerikaanse productie... Extreem luxe Range Rover "Alfa laat Chrysler topmodel bouwen" Naar Auto
Wetenschappers: doorbraak bij aidsvaccin
Video Buitenland
Twingly blog zoekenJouw blog hier

do 24 sep 2009, 10:35 Wetenschappers: doorbraak bij aidsvaccin BANGKOK - Wetenschappers zeggen voor het eerst een aidsvaccin te hebben ontwikkeld dat het risico om de ongeneeslijke ziekte op te lopen, beperkt. In een onderzoek, waaraan meer dan 16.000 mensen in Thailand vrijwillig meewerkten, bleek het vaccin het risico met ruim 31 procent te reduceren.

Ads door Google
Bestel bij Selexyz.nl
De grootste kwaliteitsboekhandel van Nederland! Bezorging of afhalen
www.Selexyz.nl/Boeken_Bestellen
16 KG Afvallen in 4 Weken
Snel & Zonder JoJo effect Niet Goed is Geld Terug. Bestel nu!
www.RDX-ultra.nl/Afvallen
Boeken Cottages
Boek nu uw verblijf tussen 4 sep & 29 jan: profiteer van €100 korting!
www.CenterParcs.nl
„Voor het eerst is aangetoond dat een vaccin tegen hiv, het virus dat aids veroorzaakt, tegen een infectie kan beschermen”, zei kolonel Jerome Kim van het Amerikaanse militaire hiv-programma in de Thaise hoofdstad Bangkok. Hij sprak van „zeer belangrijke wetenschappelijke vooruitgang”.

Aan het onderzoek van het Amerikaanse leger en het Thaise ministerie van Gezondheidszorg werkten mannen en vrouwen, in leeftijd variërend van 18 tot 30 jaar, uit twee provincies in Thailand mee. Geen van hen was met hiv besmet. Het vaccin is een combinatie van twee eerdere vaccins die het aantal infecties afzonderlijk niet bleken te verminderen, maar kennelijk wel helpen, als ze worden samengevoegd.

Het Nederlandse AIDS Fonds noemt de ontwikkeling van het nieuwe vaccin „bemoedigend”. „We zijn aangenaamd verrast dat het middel effect heeft. Dat hadden we niet verwacht omdat een eerder getest ander middel dat is gebaseerd op dezelfde theorie, niet effectief bleek”, aldus een woordvoerster van het fonds.

Het AIDS Fonds is benieuwd naar de uitkomsten van het volledige onderzoek die in oktober naar buiten worden gebracht. „Dit middel zou het eerste zijn dat in staat is de hiv-infectie te stoppen”, aldus de woordvoerster.

flosz 24 september 2009 20:15

1

quote:
eddy59 schreef:
SNELNIEUWS

Waar?

I got addicted.
News, particularly daily news,
is more addictive than crack cocaine,
more addictive than heroin,
more addictive than cigarettes.
Dan Rather

www.youtube.com/watch?v=Cklb7L0OA1c

eddy59 24 september 2009 20:17

0

gewoon in de telegraaf

flosz 24 september 2009 20:37

3

quote:
eddy59 schreef:
gewoon in de telegraaf

Zo kan het ook:
do 24 sep 2009, 10:35
Wetenschappers: doorbraak bij aidsvaccin
BANGKOK - Wetenschappers zeggen voor het eerst een aidsvaccin te hebben ontwikkeld dat het risico om de ongeneeslijke ziekte op te lopen, beperkt. In een onderzoek, waaraan meer dan 16.000 mensen in Thailand vrijwillig meewerkten, bleek het vaccin het risico met ruim 31 procent te reduceren.
Voor het eerst is aangetoond dat een vaccin tegen hiv, het virus dat aids veroorzaakt, tegen een infectie kan beschermen”, zei kolonel Jerome Kim van het Amerikaanse militaire hiv-programma in de Thaise hoofdstad Bangkok. Hij sprak van „zeer belangrijke wetenschappelijke vooruitgang”.
Aan het onderzoek van het Amerikaanse leger en het Thaise ministerie van Gezondheidszorg werkten mannen en vrouwen, in leeftijd variërend van 18 tot 30 jaar, uit twee provincies in Thailand mee. Geen van hen was met hiv besmet. Het vaccin is een combinatie van twee eerdere vaccins die het aantal infecties afzonderlijk niet bleken te verminderen, maar kennelijk wel helpen, als ze worden samengevoegd.
Het Nederlandse AIDS Fonds noemt de ontwikkeling van het nieuwe vaccin „bemoedigend”. „We zijn aangenaamd verrast dat het middel effect heeft. Dat hadden we niet verwacht omdat een eerder getest ander middel dat is gebaseerd op dezelfde theorie, niet effectief bleek”, aldus een woordvoerster van het fonds.
Het AIDS Fonds is benieuwd naar de uitkomsten van het volledige onderzoek die in oktober naar buiten worden gebracht. „Dit middel zou het eerste zijn dat in staat is de hiv-infectie te stoppen”, aldus de woordvoerster.
www.telegraaf.nl/buitenland/4910501/_...

Of zo:
www.iex.nl/forum/topic.asp?forum=228&...

AEX 938,58 0,00 0,00% 20 feb


Germany40^	22.370,40	+0,25%
BEL 20	4.369,35	0,00%
Europe50^	5.471,79	+0,20%
US30^	44.214,00	+0,07%
Nasd100^	22.087,90	+0,08%
US500^	6.119,58	+0,01%
Japan225^	38.841,70	+0,66%
Gold spot	2.931,33	-0,26%
EUR/USD	1,0497	-0,01%
WTI	72,24	-0,25%

AALBERTS NV	0,00%
ABN AMRO BANK...	0,00%
Accsys	0,00%
ACOMO	0,00%
ADYEN NV	0,00%

AALBERTS NV	0,00%
ABN AMRO BANK...	0,00%
Accsys	0,00%
ACOMO	0,00%
ADYEN NV	0,00%

Crucell « Terug naar discussie overzicht

Draadje HIV/AIDS

Meedoen aan de discussie?

Direct naar Forum

Markt vandaag

Aandelenadviezen van IEX.nl

Stijgers

Dalers